Reply Platelet Activation and Pneumonia: Is Soluble P-Selectin the Right Marker? by Violi, Francesco et al.
J A C C V O L . 6 5 , N O . 1 4 , 2 0 1 5 Letters
A P R I L 1 4 , 2 0 1 5 : 1 4 8 4 – 9 4
1493sp-selectin and membrane-bound p-selectin, a sub-
sequent single-center study (n ¼ 136) was conducted
by our group (3). We showed that the p-selectin pro-
ﬁle alone did not reliably differentiate acute coronary
syndromes from noncardiac chest pain due to inter-
individual variability and low overall sensitivity;
many patients with noncardiac chest pain had high
soluble and membrane-bound p-selectin. Finally, in a
multicenter study (n ¼ 338) in patients presenting
with chest pain, it was shown that membrane bound
p-selectin expression, an established marker of
platelet activation, was unrelated to the level of
sp-selectin, irrespective of the etiology of chest pain.
Taken together, all of these results strongly suggest
that sp-selectin cannot reliably serve as a surrogate
marker to indicate platelet activation in patients
with AMI and noncardiac chest pain (4). Regarding
CD-40L, despite the earlier enthusiasm about the
potential of this marker as a diagnostic tool, there
have been no reports that this marker has clinical
importance. Its lack of utility may be related
to artifacts associated with its measurement.
Finally, in addition to platelets, endothelial cells and
monocytes/macrophages express cyclooxygenase-2.
In states of intense inﬂammation, such as pneu-
monia, in which cyclooxygenase-2 expression is high,
elevated total serum TxB2 levels may be the result of
increased TxA2 synthesis in leukocytes or caused
by transcellular synthesis of TxA2 in platelets (5).
Therefore, we suggest that the results of the current
study must be interpreted with caution for 3 reasons:
1) the assessment of platelet activation by the pro-
posed soluble markers; 2) the elevation of sp-selectin
and TxB2 in noncardiac disease states; and 3) the prior
evidence that both soluble and membrane-bound
p-selectin are not robustly associated with proven MI.*Paul A. Gurbel, MD
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REPLY: Platelet Activation and PneumoniaIs Soluble P-Selectin the Right Marker?We thank Dr. Gurbel and colleagues for their inter-
esting comments related to our recent report showing
an association between enhanced in vivo platelet
activation and myocardial infarction in patients with
community-acquired pneumonia (CAP) (1).
The authors raise relevant questions as to whether
in vivo platelet activation occurs in patients with
pneumonia and is robustly associated with myocar-
dial infarction. The authors question in particular
the assay validity of soluble-p-selectin (sp-selectin)
and soluble CD-40L (sCD-40L) as markers of in vivo
platelet activation because in vitro artifacts or extra-
platelet sources of sp-selectin or sCD-40L render
the biological interpretation to be difﬁcult. We agree
with Dr. Gurbel and colleagues that platelets are not
the only cells activated during infections because
leukocytes may also be stimulated and potentially
contribute to thromboxane B2 over-production.
Regarding the assay validity of sp-selectin and
sCD-40L as markers of platelet activation, data are
controversial as demonstrated, for example, by an
interventional study suggesting that sCD-40L is
partly of platelet origin because it is signiﬁcantly
reduced by aspirin treatment (2). We also agree with
the authors that the increase of plasma levels of
sp-selectin and sCD-40L are not speciﬁc for acute
coronary syndrome because they may be elevated
also in patients with stable atherosclerosis or
atherosclerotic risk factors (2). Of note, with the use
of these variables as biomarkers of platelet activation,
prospective studies in patients with stable athero-
sclerosis or acute coronary syndromes demonstrated
that either sCD-40L or sp-selectin predicts poor car-
diovascular events (2).
However, regarding our report on CAP, the associ-
ation between biomarkers of platelet activation with
Letters J A C C V O L . 6 5 , N O . 1 4 , 2 0 1 5
A P R I L 1 4 , 2 0 1 5 : 1 4 8 4 – 9 4
1494cardiovascular events does not establish a cause-and-
effect relationship, which, in fact, must be supported
by interventional trials with antiplatelet drugs. We
have explored this important issue in an observational
study performed in 1,005 patients hospitalized for CAP
and followed up to 30 days after admission; at the time
of hospitalization, 390 patients (38.8%) were receiving
treatment with 100 mg of aspirin (3). During the
follow-up, 16.2% of patients died, 4.9% were aspirin
users, and 23.4 were aspirin nonusers (p < 0.001);
furthermore, patients taking aspirin experienced
fewer cardiovascular events compared with nonusers
(4.9% versus 8.3%; p ¼ 0.040). Even if the observa-
tional nature of the study does not permit a deﬁnite
conclusion, this preliminary report is in favor of a
potential role of platelets in favoring cardiovascular
events and warrants randomized clinical trials with
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